Pipeline

TH1902

SORT1+ Technology™ platform

Theratechnologies is developing a novel and targeted treatment platform in oncology based on new proprietary peptides targeting the sortilin receptor. The expression of the sortilin receptor has been documented in ovarian, triple negative breast, skin, lung, colorectal and pancreatic cancers, among others.

Targeting sortilin receptors could therefore lead to a selective delivery approach as well as a specific internalization of a number of anticancer agents that can be linked to these peptides. The use of this strategy would be a step towards personalized medicine for patients where only those likely to respond to the drug would first be identified and treated in this way, increasing the chance of a cure and minimizing health care costs.

New peptide-drug conjugates (PDC) generated through our platform are considered new chemical entities (NCEs) with pharmacodynamic and pharmacokinetic properties different from their parent compounds. These new anticancer agents should also induce less toxicity to non-cancerous cells that have no or only a fraction of sortilin receptors observed in some cancers.

TH1902

TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. The U.S. Food and Drug Administration (FDA) recently granted fast track designation to TH1902 as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy. TH1902 is the Company’s lead PDC stemming from Theratechnologies’ SORT1+ Technology™ in oncology.

TH1902 is currently being evaluated in a Phase 1 clinical trial. The Phase 1 clinical trial includes a dose-escalating part to evaluate the safety, pharmacokinetics, maximum tolerated dose (MTD) and preliminary anti-tumor activity of TH1902 administered once every three weeks in patients with advanced solid tumors refractory to available anti-cancer therapies.

Once the MTD is determined, it is planned that a total of 40 additional patients will be enrolled to evaluate the potential anti-tumor activity of TH1902 in patients with endometrial, ovarian, colorectal, pancreatic and triple negative breast cancers.

Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center is the Lead Principal Investigator of the Phase 1 trial for TH1902.

The detailed Phase 1 study protocol is available at www.clinicaltrials.gov under the identifier number: NCT04706962.

SORT1+ Technology™ is a trademark of Theratechnologies Inc.